Two pharma cos and several generic accomplices named in pay-for-delay probe
This article was originally published in Scrip
The European Commission has fired warning shots at Lundbeck and Servier in its long-running probe into the possibility that pharmaceutical companies have engaged in anti-competitive business practices. This is the first case that may lead to Commission action against companies for "pay-for-delay" tactics to keep competing generic products off the market.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.